Location Greater Boston Area, United States, North America Regions East Coast, New England Gender Female
LinkedIn View on LinkedIn
Jing Watnick is a Co-Founder, President, and Chief Executive Officer at Vigeo Therapeutics. She is a former Program Lead, Niraparib (Zejula, PARP inhibitor) at TESARO, Inc. and Program Leader & Portfolio Management at Alexion Pharmaceuticals, Inc.
Ms. Watnick received a bachelor of science in Pharmacology at Peking University and earned an MBA
in Management Strategy and Finance & Marketing at Northwestern University - Kellogg School of Management.
